主页 / 资源 / 视频 / PBPK 建模支持突破性抗癌药物的批准
PBPK 建模支持突破性抗癌药物的批准

Pharmacyclics’ (now AbbVie) Imbruvica (ibrutinib) is an anticancer drug targeting B-cell malignancies. Leveraging the US FDA’s accelerated approval programs, the company generated PBPK models using the Simcyp Simulator to inform dose, dosing regimens, and DDIs. Approved initially for mantle cell lymphoma as a breakthrough therapy, Imbruvica is now approved for multiple uses, including first-line CLL.

返回顶部
Powered by Translations.com GlobalLink OneLink Software